577 related articles for article (PubMed ID: 28498857)
1. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
Gouveia M; Jesus G; Inês M; Costa J; Borges M
Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.
Mangen MJ; Rozenbaum MH; Huijts SM; van Werkhoven CH; Postma DF; Atwood M; van Deursen AM; van der Ende A; Grobbee DE; Sanders EA; Sato R; Verheij TJ; Vissink CE; Bonten MJ; de Wit GA
Eur Respir J; 2015 Nov; 46(5):1407-16. PubMed ID: 26160871
[TBL] [Abstract][Full Text] [Related]
10. Cost-Utility Study of PCV13 Versus PPSV23 in Adults in Chile.
Biagini L; Pezzani M; Rojas R; Fuentealba F
Value Health Reg Issues; 2018 Dec; 17():194-201. PubMed ID: 30447540
[TBL] [Abstract][Full Text] [Related]
11. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
[TBL] [Abstract][Full Text] [Related]
14. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
[TBL] [Abstract][Full Text] [Related]
15. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
Stoecker C; Kim L; Gierke R; Pilishvili T
J Gen Intern Med; 2016 Aug; 31(8):901-8. PubMed ID: 26976292
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
20. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
